Peptós.LIFE — FDA Peptide Tracker: Regulatory Updates https://peptos.life/fda-tracker/news A dated, sourced changelog of the peptide regulatory landscape — PCAC, GLP-1/503B, RFK-14 reclassification, and enforcement. Primary FDA sources only. Compounded medications are not FDA-approved. en-us Fri, 24 Jul 2026 00:00:00 GMT 1440 Day 2: the FDA panel backed Semax and Epitalon, and rejected DSIP — six of seven peptides advanced. https://peptos.life/fda-tracker/news/fda-panel-recommends-semax-epitalon-rejects-dsip pcac-july-day2-outcome PCAC Fri, 24 Jul 2026 00:00:00 GMT On July 24, 2026 the PCAC recommended Semax (8–5) and Epitalon (7–4) for the 503A Bulks List but narrowly rejected Emideltide/DSIP (6–7, one abstention). Across both days six of seven peptides advanced. A recommendation is not approval, not authorization to compound, and not availability; a rejection is not a new prohibition. Every verdict dot stays amber. The FDA advisory panel backed BPC-157, KPV, TB-500 and MOTS-c, here's what that does and doesn't mean. https://peptos.life/fda-tracker/news/fda-panel-recommends-bpc-157-tb-500-kpv-mots-c pcac-july-outcome PCAC Thu, 23 Jul 2026 00:00:00 GMT On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500 and MOTS-c to the 503A Bulks List, against its own scientists' advice. A recommendation is not approval, not authorization, and not availability: FDA rulemaking must follow, realistically late 2026 into 2027. Verdict dots stay amber; the regulatory status advances to "PCAC recommended, rulemaking pending." Day 2 (DSIP, Semax, Epitalon) reviewed Jul 24, outcome pending. FDA schedules July PCAC vote on BPC-157, TB-500 and five more — what it means. https://peptos.life/fda-tracker/news/fda-pcac-july-2026-peptide-vote pcac-july-scheduled PCAC Wed, 10 Jun 2026 00:00:00 GMT The FDA's Pharmacy Compounding Advisory Committee will review seven peptides on July 23–24, 2026. The vote is advisory: a favorable recommendation leads to rulemaking, not instant availability. We'll publish the outcome the same day. GLP-1 503B exclusion: the comment window closes June 29. https://peptos.life/fda-tracker/news/glp1-503b-exclusion-comments-close-june-29 glp1-503b-comment-window GLP-1 / 503B Wed, 20 May 2026 00:00:00 GMT The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from 503B bulk compounding. Public comments close June 29, 2026. The approved branded products remain available; the proposal targets compounded supply. Category 2 “removal” isn't authorization — reading the April 2026 change honestly. https://peptos.life/fda-tracker/news/category-2-removal-is-not-authorization cat2-removal-honest-read Peptide reclassification (RFK-14) Sat, 02 May 2026 00:00:00 GMT Some are reading the April 2026 removal of peptides from compounding Category 2 as a green light. The more authoritative legal reading does not: removal is not the same as Category 1, the Bulks List, or availability. The verdict dot stays amber. What the RFK-14 peptide reclassification actually means. https://peptos.life/fda-tracker/news/what-the-rfk-14-peptide-reclassification-means rfk14-reclassification-explainer Peptide reclassification (RFK-14) Wed, 22 Apr 2026 00:00:00 GMT “RFK-14” is shorthand for the group of peptides swept into the 2026 compounding-policy review. Reclassification changes how — and whether — a licensed pharmacy may compound them. It is a regulatory mechanism, not a clinical endorsement.